Lidocaine (Lignocaine)
(EMLA, Intubeaze, Lignadrin, Lignol, Locaine, Locovetic,
Lidoderm*) POM-V
Formulations: Injectable: 1%, 2% solutions (some contain
adrenaline). Topical: 2% solution (Intubeaze), 4% solution (Xylocaine);
2.5% cream with prilocaine (EMLA); 5% transdermal patches
(Lidoderm).
Action: Local anaesthetic action is dependent on reversible
blockade of the sodium channel, preventing propagation of an action
potential along the nerve fibre. Sensory nerve fibres are blocked
before motor nerve fibres, allowing a selective sensory blockade at
low doses. Lidocaine also has class 1b antiarrhythmic actions,
decreasing the rate of ventricular firing, action potential duration and
absolute refractory period, and increasing relative refractory period.
Lidocaine has a rapid onset of action and intermediate duration of
action. Addition of adrenaline to lidocaine increases the duration of
action by reducing the rate of systemic absorption.
Use: Provision of local or regional analgesia using perineural,
infiltration, local i.v. or epidural techniques. Intratesticular lidocaine
has been shown to reduce haemodynamic responses to castration in
dogs and cats and is recommended to provide intraoperative
analgesia during castration and reduce the requirement for inhalant
anaesthetic agents. It is generally recommended that adrenaline-free
solutions be used for epidural administration. Also used to provide
systemic analgesia when given i.v. by continuous rate infusion.
First-line therapy for rapid or haemodynamically significant
ventricular arrhythmias. May also be effective for some
supraventricular arrhythmias, such as bypass-mediated
supraventricular tachycardia, and for cardioversion of acute-onset or
vagally-mediated atrial fibrillation. Widely used topically to
desensitize mucous membranes (such as the larynx prior to
intubation). EMLA cream is used to anaesthetize the skin before
vascular cannulation. It must be placed on the skin for approximately
45–60 minutes to ensure adequate anaesthesia; covering the skin
with an occlusive dressing promotes absorption. EMLA is very useful
to facilitate venous catheter placement in small puppies and kittens.
The pharmacokinetics of transdermal lidocaine patches have been
evaluated in dogs and cats; bioavailability of transdermal lidocaine is
low in cats and dogs compared with humans. The analgesic efficacy
and clinical usefulness of transdermal lidocaine has not yet been
evaluated in either species. Infusions of lidocaine reduce the inhaled
concentrations of anaesthetic required to produce anaesthesia and
prevent central sensitization to surgical noxious stimuli. Systemic
lidocaine is best used in combination with other analgesic drugs to
achieve balanced analgesia. Lidocaine will accumulate after
prolonged administration, leading to a delayed recovery. Cats are
very sensitive to the toxic effects of local anaesthetics, therefore, it is
important that doses are calculated and administered accurately.
Safety and handling: Normal precautions should be observed.
Contraindications: Do not give to cats by continuous rate infusion
during the perioperative period due to the negative haemodynamic
effects. Do not give lidocaine solutions containing adrenaline i.v. Do
not use solutions containing adrenaline for complete ring block of an
extremity because of the danger of ischaemic necrosis.
Adverse reactions: Depression, seizures, muscle fasciculations,
vomiting, bradycardia and hypotension. If reactions are severe,
decrease or discontinue administration. Seizures may be controlled
with i.v. diazepam or pentobarbital.